Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kise SYK (Spleen Tyrosine Kise or p72 Syk or SYK or EC 2.7.10.2) - Overview
Tyrosine Protein Kise SYK (Spleen Tyrosine Kise or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tyrosine Protein Kise SYK (Spleen Tyrosine Kise or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kise SYK (Spleen Tyrosine Kise or p72 Syk or SYK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AB Science SA
Alexion Pharmaceuticals Inc
Aptose Biosciences Inc
Archer Pharmaceuticals Inc
Asa BioSciences LLC
Beijing Hanmi Pharmaceutical Co Ltd
Calithera Biosciences Inc
Clevexel Pharma SA
CSPC Pharmaceutical Group Ltd
Genosco Inc
GlaxoSmithKline Plc
Hutchison MediPharma Ltd
IACTA Pharmaceuticals Inc
Japan Tobacco Inc
Kronos Bio Inc
Levolta Pharmaceuticals Inc
no Biotherapeutics Inc
Origenis GmbH
Pulmatrix Inc
Rigel Pharmaceuticals Inc
Taiho Pharmaceutical Co Ltd
Tyrosine Protein Kise SYK (Spleen Tyrosine Kise or p72 Syk or SYK or EC 2.7.10.2) - Drug Profiles
AB-8779 - Drug Profile
Product Description
Mechanism Of Action
cerdulatinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
cevidoplenib - Drug Profile
Product Description
Mechanism Of Action
History of Events
CVXL-0074 - Drug Profile
Product Description
Mechanism Of Action
History of Events
entospletinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
fostamatinib disodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
GNS-1653 - Drug Profile
Product Description
Mechanism Of Action
GS-492429 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GSK-2646264 - Drug Profile
Product Description
Mechanism Of Action
History of Events
gusacitinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
HM-43239 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IC-265 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IC-270 - Drug Profile
Product Description
Mechanism Of Action
History of Events
JTE-852 - Drug Profile
Product Description
Mechanism Of Action
lanraplenib succite - Drug Profile
Product Description
Mechanism Of Action
History of Events
mivavotinib citrate - Drug Profile
Product Description
Mechanism Of Action
History of Events
nilvadipine - Drug Profile
Product Description
Mechanism Of Action
History of Events
piceatannol albumin bound - Drug Profile
Product Description
Mechanism Of Action
History of Events
PRT-2761 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PUR-1800 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit SYK and JAK for Rheumatoid Arthritis and Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit SYK for Ocular Inflammation - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit H1-SYK for Unspecified Ophthalmic Diseases - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Spleen Tyrosine Kise for Immunology and Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
sovleplenib - Drug Profile
Product Description
Mechanism Of Action
History of Events
SYHX-1901 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TAS-05567 - Drug Profile
Product Description
Mechanism Of Action
Tyrosine Protein Kise SYK (Spleen Tyrosine Kise or p72 Syk or SYK or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kise SYK (Spleen Tyrosine Kise or p72 Syk or SYK or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kise SYK (Spleen Tyrosine Kise or p72 Syk or SYK or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Mar 08, 2022: Rigel announces publication of data from phase 2 clinical study of fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia in the American Jourl of Hematology
Jan 12, 2022: HUTCHMED receives Breakthrough Therapy desigtion in Chi for HMPL-523 for treatment of primary immune thrombocytopenia
Dec 21, 2021: Fostamatinib meets primary endpoint in phase 3 trial in Japan for treatment of chronic immune thrombocytopenia
Dec 14, 2021: HUTCHMED highlights HMPL-523 clinical data presented at the 2021 ASH Annual Meeting
Dec 13, 2021: HM43239 demonstrates durable clinical benefit in acute myeloid leukemia
Dec 06, 2021: Kronos Bio announces first patient dosed in AGILITY phase 3 clinical trial of entospletinib in patients with newly diagnosed NPM1-mutated acute myeloid leukemia
Nov 15, 2021: Rigel sharpens focus on its advanced portfolio opportunities
Nov 08, 2021: HUTCHMED highlights HMPL-523 clinical data to be presented at the 2021 ASH Annual Meeting
Oct 27, 2021: HUTCHMED initiates ESLIM-01, a phase III trial of HMPL-523 in patients with immune thrombocytopenia in Chi
Sep 01, 2021: Data from NIH/NHLBI-sponsored phase 2 trial of Fostamatinib in hospitalized COVID-19 patients published in clinical infectious diseases
Aug 13, 2021: Rigel Pharmaceuticals provides update on COVID-19 program
Jul 27, 2021: Kronos Bio announces FDA clearance of investigatiol new drug application for lanraplenib (LANRA) for treatment of patients with acute myeloid leukemia (AML)
Jul 14, 2021: New TAVALISSE data alyses to be presented at Intertiol Society on Thrombosis and Haemostasis (ISTH) 2021 Congress
Jun 29, 2021: Fostamatinib selected for NIH ACTIV-4 COVID-19 clinical trial
Apr 22, 2021: Asa BioSciences to present additiol efficacy data from chronic hand eczema Phase 2b trial of oral SYK/JAK inhibitor Gusacitinib at AAD VMX late-breaking session
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AB Science SA, 2022
Pipeline by Alexion Pharmaceuticals Inc, 2022
Pipeline by Aptose Biosciences Inc, 2022
Pipeline by Archer Pharmaceuticals Inc, 2022
Pipeline by Asana BioSciences LLC, 2022
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, 2022
Pipeline by Calithera Biosciences Inc, 2022
Pipeline by Clevexel Pharma SA, 2022
Pipeline by CSPC Pharmaceutical Group Ltd, 2022
Pipeline by Genosco Inc, 2022
Pipeline by GlaxoSmithKline Plc, 2022
Pipeline by Hutchison MediPharma Ltd, 2022
Pipeline by IACTA Pharmaceuticals Inc, 2022
Pipeline by Japan Tobacco Inc, 2022
Pipeline by Kronos Bio Inc, 2022
Pipeline by Levolta Pharmaceuticals Inc, 2022
Pipeline by Nano Biotherapeutics Inc, 2022
Pipeline by Origenis GmbH, 2022
Pipeline by Pulmatrix Inc, 2022
Pipeline by Rigel Pharmaceuticals Inc, 2022
Pipeline by Taiho Pharmaceutical Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Dormant Products, 2022 (Contd..4)
Dormant Products, 2022 (Contd..5)
Discontinued Products, 2022
Discontinued Products, 2022 (Contd..1)